HeartSciences Inc. (HSCSW) shareholders
Close on Oct 30, 2026Market cap $15.89MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| John H. Matthews Joint filing with Matthews Holdings Southwest Inc. (8.10%) | 5,241,758 | 8.10% | 13G (passive) | Nov 15, 2023 |
| Icahn School Of Medicine At Mount Sinai ("ismms") | 4,854,853 | 9.90% | 13G (passive) | Nov 16, 2023 |
| Digital Currency Group, Inc. Joint filing with Fortitude Mining Holdings, Inc. (9.40%) | 411,522 | 9.40% | 13D (active) | Aug 12, 2026 |
| Fields Ephraim G | 265,218 | 8.10% | 13G (passive) | Jun 23, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HSCSW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Clear Street Group Inc. | 270,770 | – | $13.59K | – | 0.00% |
| Citadel Advisors LLC | 187,495 | – | $9.56K | −5,092 | 0.00% |
| UBS Group AG | 1,086 | – | $54 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 3 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q1 2026 | 3 | 0M | 0 / 1 | 1 / 0 | 0M | 0M |
| Q4 2025 | 3 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q3 2025 | 3 | 0M | 2 / 0 | 1 / 1 | 0M | 0M |
| Q2 2025 | 3 | 1M | 0 / 1 | 2 / 0 | 0M | 0M |
| Q1 2025 | 3 | 1M | 0 / 1 | 1 / 2 | 0M | 0M |
| Q4 2024 | 5 | 1M | 2 / 2 | 1 / 0 | 0M | 0M |
| Q3 2024 | 3 | 1M | 0 / 1 | 1 / 2 | 0M | 0M |
| Q2 2024 | 5 | 1M | 2 / 3 | 0 / 2 | 1M | 0M |
| Q1 2024 | 5 | 0M | 1 / 0 | 3 / 0 | 0M | 0M |
| Q4 2023 | 4 | 0M | 1 / 1 | 0 / 2 | 0M | 0M |
| Q3 2023 | 5 | 0M | 1 / 3 | 0 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Andrew Simpson | See Remarks, Director | 499,382 | Jun 24, 2026 |
| Danielle Watson | See Remarks | – | Jul 9, 2026 |
| Mark T. Hilz | See Remarks | 4,793 | Dec 22, 2025 |
| David R. Wells | Director | – | Jan 12, 2026 |
| Bruce Bent | Director | 1,638 | Jan 12, 2026 |
| Brian Szymczak | Director | 6,060 | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andrew Simpson See Remarks, Director | Jun 22, 2026 | Award | +425,000 | – | – | 499,382 |
| Andrew Simpson See Remarks, Director | Nov 28, 2025 | Award | +70,000 | – | – | 74,382 |
| Mark T. Hilz COO, Secretary and Director | Jul 29, 2025 | Sale(10b5-1 plan) | −4,416 | $3.54 | $15.63K | 4,752 |
| Andrew Simpson See Remarks, Director | Aug 12, 2024 | Other | +17 | – | – | 7,629 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of HeartSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,198 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark T. Hilz Officer, Director | Jul 29, 2025 | 4,416 | $15.72K | Jul 29, 2025 | PURCHASE |